Drug Profile
BIM 2b
Alternative Names: BIM-2bLatest Information Update: 14 Sep 2023
Price :
$50
*
At a glance
- Originator Beta Innov
- Class Antineoplastics; Small molecules
- Mechanism of Action L-lactate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glioblastoma
Most Recent Events
- 14 Sep 2023 Discontinued - Preclinical for Glioblastoma in France (unspecified route), prior to September 2023
- 28 Jan 2019 No recent reports of development identified for preclinical development in Glioblastoma in France
- 10 Aug 2016 Preclinical development is ongoing in France